- [5] Ann Rheum Dis. 2020 Jan;79(1):77-87.
 [6] Arthritis Res Ther 2018 Apr 10;20(1):65.
 [7] Intern Med. 2014;53(3):171-6.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.2703

AB1065 VISIT COMPLIANCE IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER: RESULTS FROM A GAZI UNIVERSITY FMF COHORT

R. Bilici Salman¹, A. Avanoğlu Güler¹, H. Satış¹, H. Karadeniz¹, H. Babaoglu¹, N. Atas¹, S. Haznedaroglu¹, M. A. Ozturk¹, B. Goker¹, A. Tufan¹. ¹Gazi University Faculty of Medicine Division of Rheumatology Internal Medicine Department, Internal Medicine Department, Ankara, Turkey

Background: Follow-up in all rheumatologic patients is critical, particularly Familial Mediterranean Fever (FMF). Current recommendations for all experts by the EULAR state that patients with FMF should be evaluated 6-monthly intervals to monitor the character and frequency of the attacks and the acute phase response. Disease-related complications such as amyloidosis can be *asymptomatic* and need only a careful follow-up.

Objectives: to quantify this phenomenon and to find predictive factors of visit compliance in patients with FMF.

Methods: The study included 474 adult patients with a diagnosis of FMF who followed at the outpatient rheumatology clinic of tertiary university hospital, from January 2018 to December 2018. Demographic, socioeconomic data, family history, comorbid disease, medication history, characteristics, the International Severity Score for FMF (ISSF), autoinflammatory disease damage index (ADDI) were recorded. Visit compliance was defined as the presence of two visits in the outpatient rheumatology clinic for FMF last one year for the purposes set out in EULAR suggestion. Those who had fewer than two visits in the last one year were considered noncompliant.

Results: 230 (48.5%) were compliant while 244 (51.5 %) patients were noncompliant with their rheumatology visit. Both compliant and noncompliant patients had similar median age and disease duration. Female sex and being married was increased the visit compliance. The results of the logistic regression model exploring factors associated with compliance indicated that presence of family history in parents, absence of family history in sibling, treatment with biologic agents, other drug using, presence of more than 2 attacks except fever and adequate medical care were important predictors of visit compliance.

Table 1. Descriptive characteristics of the patients with FMF, n=474

Variable	Compliant (n=230)	Noncompliant (n=244)	P value
Gender of patient (F)	142(61.7)	147(60.2)	0.73
Age, years*	35(28-42.5)	34(27-44.2)	0.88
Being Married	152(66.1)	146(59.8)	0.15
Disease duration, years*	22(14-31)	22(15-31)	0.71
Number of index flare* within last 12-month	6.7(1-10)	5(3-10)	<0.001
Family history of parents	54(23.5)	39(16.0)	0.04
Family history of sibling	73(32.9)	102(43.4)	0.02
Comorbid disease presence	73(31.7)	55(22.5)	0.02
Treatment			<0.001
Colchicine	230 (94.1)	180(78.6)	
Anakinra&Canakinumab	134(5.3)	49(21.4)	
Colchicine response presence	127(55.2)	126(52.3)	0.52
Drug using except FMF	74(32.2)	44(18.0)	<0.001
Presence of 2 attacks except fever	90 (39.1)	68(27.9)	0.009
Chronic peripheral arthritis	16(7.0)	7(2.9)	0.03
Amyloidosis	18(7.8)	9(3.7)	0.05
Proteinuria	23(10.8)	8(3.6)	0.004
Adequate medical care	161(70.0)	132(54.8)	<0.001
ISSF severity score*	3(2-4)	3(2-4)	0.02
ADDI index*	1(0-1)	1(0-1)	0.05

Conclusion: In conclusion, if FMF patients visit compliance increase, their functionality, medication adherence and quality of life will increase and flares and complication of disease can decrease. Thus, we highlight some recommendations for FMF specialist, patients and health care providers to improve outcomes.

Table 2. Multivariate logistic regression analysis for predictive factors of visit compliance of the patients with FMF, n=430

	Adj. OR	%95 CI**	p
Family history in parents (positive history vs negative)	1,8	1,0-3,1	0.03
Family history in sibling (negative history vs positive)	1,9	1,2-3,1	0.004
Comorbid disease status	1,3	0,7-2,5	0.32
Treatment (anakinra&canakinumab vs colchicine)	3,7	1,7-8,2	0.001
Drug using (other drugs vs FMF drugs)	2,2	1,1-4,4	0.01
More than 2 attacks except fever	2,3	1,2-4,0	0.004
Chronic peripheral arthritis	2,3	0,8-6,6	0.10
Proteinuria	2,2	0,7-6,7	0.14
Adequate medical care	1,9	1,2-3,1	0.003
Number of index flare within last 12-month	0,9	0,9-1,0	0.38
ISSF severity score	0,8	0,7-1,1	0.30

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.4675

AB1066 EFFICACY AND SAFETY OF APREMILAST IN BEHÇET DISEASE PATIENTS

E. Vicens Bernabeu¹, E. Grau García¹, C. Alcañiz Escandell¹, F. M. Ortiz Sanjuan¹, R. Gonzalez Mazario¹, M. De la Rubia Navarro¹, C. Pávez Perales¹, S. Leal Rodríguez¹, J. Ivorra Cortés¹, L. Gonzalez Puig¹, I. Chalmeta Verdejo¹, R. Neguerolles Albuixech¹, I. Martínez Cordellat¹, J. J. Frago-Gil¹, J. E. Oller Rodríguez¹, C. Nájera Herranz¹, I. Cánovas Olmos¹, J. A. Román Ivorra¹. ¹HUP La Fe, Rheumatology Department, Valencia, Spain

Background: Apremilast (APR), a small molecule inhibitor of phosphodiesterase-4, has been shown to be effective in the treatment of oral and genital ulcers in Behçet's disease (BD). BD is a systemic vasculitis with great heterogeneity of symptoms and manifestations. It can affect the blood vessels, mucosa, skin, joints, eyes, nervous system and digestive system. APR is indicated for treatment of oral ulcers in BD in some countries such as the USA and Japan.

Objectives: To evaluate the efficacy and safety of APR treatment in BD patients.

Methods: Single-center descriptive study of BD patients on APR treatment from February 2017 to December 2019. Demographic, clinical and analytical data were collected.

Results: 10 patients (9 women) were included, with a mean age at the beginning of APR treatment of 37±12 years and a mean disease evolution of 100±105 months. 8 of them showed HLAB51 positivity.

Before treatment with APR, 4 patients were refractory to DMARDs (2 MTX, 2 AZA) and one patient to 2 anti-TNF (ADA, IFX). All patients were under treatment with colchicine and 5 with steroids before APR therapy. The concomitant treatment with APR were: corticosteroids (5), NSAIDs (2), colchicine (8), MTX (2), AZA (2). The main symptoms at the beginning of the APR treatment were: oral ulcers (100%), genital ulcers (60%) and arthritis/arthritis (90%). We observed a clinical improvement after 3 months of treatment of 90% of oral ulcers, 100% of genital ulcers and 55% of joint symptoms. The patients had a mean follow-up of 37±12 months and they maintain the therapy response during the APR treatment. Patients presented adverse events, some of them transitory: headache (5), diarrhea (5), nausea (3), dysphagia (1), tremors (2), herpes zoster (1) and autolytic ideation (1). The treatment was withdrawn in 4 patients with a mean duration of 11 ± 13 months. 2 of the 4 adverse events were by autolytic ideation and nausea, 1 for genic desire and 1 for persistence of joint injury. The APR doses were reduced to 30mg per day in 4 patients, resolving the adverse events and persisting with a good response. In addition, dose reduction of colchicine and prednisone was achieved in 4 patients.

We observed other previous manifestations of BD such as uveitis (4), neurobehçet (3), cutaneous (folliculitis/pseudofolliculitis) (4) and venous thrombosis (1). Cutaneous manifestations were resolved and the rest of previous manifestations remain without clinical changes during the follow-up.

Conclusion: We observed an improvement in the most common manifestations of BD and a safety profile similar to those described in other studies. We observed a resolution of mucocutaneous manifestations, a variable response in joint manifestations and stability in neurological manifestations. Adverse effects referred included gastrointestinal and headache, most of which were transient and were resolved with adjustment of treatment.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.5330

AB1067 CASE OR FAMILY? FROM 2 CHINESE FCAS3 CHILDREN WITH PLCG2 MUTATION TO THEIR FAMILIES.

W. Wang¹, S. Yang¹, Z. Yu¹, M. Wei¹, L. Zhong¹, H. Song¹. ¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Pediatrics, Beijing, China